This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Product Information
METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $3.1832 per ML under NDC 63323012310. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 26, 1999. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the METHOTREXATE SODIUM market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323012310
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040263FDA Approved
2/26/1999
TE Code
AP
On Market Since
9/10/2001
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 28.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1832 per ML |
|---|---|
| All-time high | $3.5278 (Jul 15, 2015) |
| All-time low | $2.4714 (Nov 28, 2013) |
| 52-week high | $3.3602 |
| 52-week low | $3.1283 |
| Median price | $3.1986 |
| Average price | $3.1758 |
| Largest weekly change | -20.7% (Jul 17, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the METHOTREXATE SODIUM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
METHOTREXATE SODIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $3.1832 per ML (NDC 63323012310), effective Sep 30, 2026.
How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has risen 28.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?
Since Nov 28, 2013, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $2.4714 (Nov 28, 2013) to a high of $3.5278 (Jul 15, 2015), with a median of $3.1986 per ML.
Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of METHOTREXATE 250 MG/10 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METHOTREXATE 250 MG/10 ML VIAL?
METHOTREXATE 250 MG/10 ML VIAL (NDC 63323012310) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Is METHOTREXATE 250 MG/10 ML VIAL in shortage?
Yes — NDC 63323012310 is currently listed in FDA's drug shortage database (posted Mar 13, 2023).